Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Buy” by Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been assigned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $26.43.

Several equities research analysts have weighed in on CPRX shares. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Citigroup assumed coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Bank of America began coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, March 7th. They set a “buy” rating and a $23.00 target price for the company. Finally, StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 25,000 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares of the company’s stock, valued at $2,045,678.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 12.10% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Boston Partners lifted its position in Catalyst Pharmaceuticals by 965.2% during the fourth quarter. Boston Partners now owns 1,541,660 shares of the biopharmaceutical company’s stock worth $25,610,000 after buying an additional 1,396,930 shares in the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Catalyst Pharmaceuticals by 64.0% in the 3rd quarter. Jupiter Asset Management Ltd. now owns 897,046 shares of the biopharmaceutical company’s stock worth $10,486,000 after acquiring an additional 350,184 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in shares of Catalyst Pharmaceuticals by 110.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 636,366 shares of the biopharmaceutical company’s stock worth $7,439,000 after acquiring an additional 333,562 shares during the period. LSV Asset Management boosted its position in shares of Catalyst Pharmaceuticals by 25.6% during the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock valued at $14,505,000 after acquiring an additional 253,100 shares during the last quarter. Finally, Clark Estates Inc. NY purchased a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at about $2,198,000. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ CPRX opened at $14.68 on Friday. Catalyst Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $17.76. The firm has a market cap of $1.73 billion, a P/E ratio of 24.07, a P/E/G ratio of 0.81 and a beta of 0.89. The business’s 50 day moving average price is $15.50 and its 200 day moving average price is $14.61.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The business had revenue of $110.57 million for the quarter, compared to the consensus estimate of $105.78 million. As a group, research analysts expect that Catalyst Pharmaceuticals will post 1.81 earnings per share for the current year.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.